General
Preferred name
LEFLUNOMIDE
Synonyms
4-Isoxazolecarboxamide, 5-methyl-n-(4-(trifluoromethyl)phenyl)- ()
HWA486 ()
RS-34821 ()
SU101 ()
HWA486, RS-34821, SU101, Arava ()
Leflunomide (HWA486) ()
SULOL ()
HWA-486 ()
LEFLUNOMIDA ()
SU-101 ()
NSC-759864 ()
NSC-677411 ()
Leflunomide Zentiva (previously Leflunomide Winthrop) ()
LEFLUNOMIDE RATIOPHARM ()
LEFLUNOMIDE MEDAC ()
REPSO ()
L04AA13 ()
LEFLUNOMIDE TEVA ()
LEFLUNOMIDE WINTHROP ()
Arava ()
Leflunomide-d4 ()
P&D ID
PD000803
CAS
75706-12-6
210165-51-8
1189987-23-2
Tags
available
prodrug
drug
Approved by
EMA
FDA
First approval
1998
Drug indication
Arthritis
Coronavirus Disease 2019 (COVID-19)
Multiple sclerosis
Rheumatoid arthritis
Drug Status
approved
withdrawn
investigational
Max Phase
4.0
Structure
Probe scores
P&D probe-likeness score
[[ v.score ]]%
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
ROE The active metabolite is eliminated by further metabolism and subsequent renal excretion as well as by direct biliary excretion. In a 28 day study of drug elimination (n=3) using a single dose of radiolabeled compound, approximately 43% of the total radioactivity was eliminated in the urine and 48% was eliminated in the feces. It is not known whether leflunomide is excreted in human milk.; Many drugs are excreted in human milk, and there is a potential for serious adverse reactions in nursing infants from leflunomide.
DESCRIPTION Inhibits dihydroorotate dehydrogenase. (GtoPdb)
DESCRIPTION Leflunomide is a pyrimidine synthesis inhibitor, inhibiting dihydroorotate dehydrogenase (DHODH), and acts as a disease-modifying antirheumatic agent.
PRICE 29
DESCRIPTION Immunosuppressive; its metabolite, a malononitrile derivative, inhibits dihydroorotate dehydrogenase (in the de novo pyrimidine synthesis pathway) and several protein tyrosine kinases (LOPAC library)
DESCRIPTION Dihydroorotate dehydrogenase inhibitor (Tocriscreen Total)
DESCRIPTION Leflunomide is a pyrimidine synthesis inhibitor, inhibiting dihydroorotate dehydrogenase. It is used as an immunosuppressant agent. (Enamine Bioactive Compounds)
DESCRIPTION Leflunomide (HWA486) is an immunomodulatory agent used in the therapy of rheumatoid arthritis and psoriatic arthritis. (TargetMol Bioactive Compound Library)
Cell lines
8
Organisms
7
Compound Sets
36
AdooQ Bioactive Compound Library
A10521
Axon Medchem Screening Library
3164
Cayman Chemical Bioactives
14860
26448
CeMM library of unique drugs (CLOUD)
ChEMBL Approved Drugs
CHEMBL960
ChEMBL Drugs
CHEMBL960
Concise Guide to Pharmacology 2017/18
6825
CZ-OPENSCREEN Bioactive Library
Drug Repurposing Hub
DrugBank
DB01097
DrugBank Approved Drugs
DB01097
DrugCentral
1552
DrugCentral Approved Drugs
1552
DrugMAP
DM9LYXQ
DMR8ONJ
DrugMAP Approved Drugs
DMR8ONJ
DrugMatrix
Enamine Bioactive Compounds
EBC-08359
Enamine BioReference Compounds
EU-OPENSCREEN Bioactive Compound Library
EOS101397
EUbOPEN Chemogenomics Library
EUB0000533
Guide to Pharmacology
6825
JUMP-Target 1 Compound Set
3899
LINCS compound set
10414-101
LOPAC library
LSP-MoA library (Laboratory of Systems Pharmacology)
CHEMBL960
MedChem Express Bioactive Compound Library
HY-B0083
NPC Screening Collection
Pandemic Response Box
Prestwick Chemical Library
ReFrame library
Selleckchem Bioactive Compound Library
Leflunomide
TargetMol Bioactive Compound Library
T1159
The Spectrum Collection
Tocriscreen Total
Withdrawn 2.0
EMA25
ZINC Tool Compounds
ZINC000000004840
External IDs
48
Properties
(calculated by RDKit )
Molecular Weight
270.06
Hydrogen Bond Acceptors
3
Hydrogen Bond Donors
1
Rotatable Bonds
2
Ring Count
2
Aromatic Ring Count
2
cLogP
3.25
TPSA
55.13
Fraction CSP3
0.17
Chiral centers
0.0
Largest ring
6.0
QED
0.91
Structural alerts
0
No structural alerts detected
Related compounds
Custom attributes
(extracted from source data)
MOA
dihydroorotate dehydrogenase inhibitor
dihydroorotate dehydrogenase inhibitor, PDGFR tyrosine kinase receptor inhibitor
Target
Dihydroorotate Dehydrogenase
AHR
DHODH
Protein-tyrosine kinase 2
AHR, DHODH, PTK2B
DHODH inhibitor
PTK2B
Bacterial
Endogenous Metabolite
AhR,Dehydrogenase
Indication
rheumatoid arthritis
ATC
L04AA13
Therapeutic Class
Antiinflammatory Agents
Antiviral Agents
Pathway
Anti-infection
Metabolic Enzyme/Protease
Immunology/Inflammation
Metabolism
Recommended Cell Concentration
10 uM
Source data